drugset / Trial / NCT02611921
Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder
Phase 1
Completed
21 enrolled
Children's Hospital Medical Center, Cincinnati
Cures Within Reach · collabRoivant Sciences, Inc. · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of the study is to determine if intranasal ketamine shows initial evidence of safety, tolerability and efficacy for the treatment of social impairment in individuals with Autism Spectrum Disorder.
Timeline
- Start
- 2015-12-22
- Primary completion
- 2018-05-07
- Completion
- 2018-05-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketamine | Small molecule | — | Intranasal |